Understanding genetic influences and biomarkers in heart failure management
Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
This study is trying to find new biological markers in heart failure patients to see if they can help doctors better understand who will respond to treatments and who won't.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Karolinska University Hospital Academic / other |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT06435585 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes the SwedeHF registry, the largest heart failure registry globally, to collect and analyze biological samples from heart failure patients across Sweden. The study aims to create a high-quality biobank linked to the registry, which will include blood plasma, whole blood, and urine samples for genetic, proteomic, and metabolomic analyses. By examining these samples, researchers hope to identify novel biomarkers that can help differentiate between responders and non-responders to heart failure treatments. This initiative will enhance future research opportunities within the national heart failure registry.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with heart failure who have provided informed consent and are registered in the SwedeHF registry.
Not a fit: Patients who have recently donated plasma or blood, or those with conditions that may affect their participation or the study's results, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment strategies for heart failure patients based on genetic and biomarker profiles.
How similar studies have performed: Other studies utilizing biobanks and registries for heart failure research have shown promise, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Written informed consent 2. Heart failure defined by symptoms and signs of heart failure as judged by the local investigator 3. Registered in SwedeHF Exclusion Criteria: 1. Plasma donation within 1 month of enrolment or any blood donation/blood loss \>500 mL during the 3 months prior to enrolment 2. Previous allogeneic bone marrow transplant (genetics) 3. In the opinion of the investigator, condition/s that may either put the patient at risk on participation or influence the results or the patient's ability to participate in the study.
Where this trial is running
Stockholm
- Karolinska University hospital — Stockholm, Sweden (Recruiting)
Study contacts
- Study coordinator: Camilla Hage, Ass prof
- Email: camilla.hage@regionstockholm.se
- Phone: +46 (0)703340660
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.